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robust. CONCLUSIONS: In the treatment of schizophrenia, quetiapine XR dominates 
quetiapine IR due to lower cost, reduced relapse and hospitalization rate and domi-
nates paliperidone due to lower cost. REFERENCE: Edwards NC et al. Pharmaco-
economics 2005;23(Suppl. 1):75–89.
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COST AND EFFECTIVENESS OF FLUPENTIXOL COMPARED TO OTHER 
FIRST AND SECOND GENERATION ANTIPSYCHOTIC AGENTS FOR 
THE TREATMENT OF SCHIZOPHRENIA IN ROUTINE CARE
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OBJECTIVES: To analyse effectiveness of ﬂupentixol compared to other ﬁrst and 
second generation antipsychotics for the treatment of schizophrenia in routine care. 
METHODS: A retrospective cohort study was conducted using administrative data 
from four sickness funds with a combined number of 12.6 million insured. Patients 
discharged from hospital with an ICD-10 diagnosis of schizophrenia in 2003 were 
followed for 12 months. Rehospitalisation during follow-up was analysed using a 
hurdle regression model. Differences in treatment costs, deﬁned as cost of pharmaceu-
tical and cost of inpatient care, were analysed assuming a gamma distribution for 
treatment costs and using a log-link-function. To control for possible confounding, 
the models adjusted for age, gender, and prior hospitalisations due to schizophrenia 
in 2000, 2001 and 2002. RESULTS: A total of 8610 insured were included, of which 
177 treated with ﬂupentixol during follow-up, while 429 and 2284 were treated with 
other ﬁrst and second generation antipsychotics, respectively. Compared to patients 
treated with ﬂupentixol (predicted hospitalisation for the average patient: 19 days), 
predicted hospitalisation did not differ signiﬁcantly for patients treated with other ﬁrst 
(16.9 days, p  0.0919) or second generation antipsychotics (19.5 days, p  0.1418). 
Predicted treatment costs for the average patient (age  41.5 years, male, prior hospi-
talisation 26.7 days per year) were a4384 if treated with ﬂupentixol, a7021 if treated 
with an other ﬁrst generation antipsychotic, and a6819 if treated with a second genera-
tion antipsychotic. Differences in treatment costs between ﬁrst and second generation 
antipsychotics increased with severity. CONCLUSIONS: The effectiveness of ﬂupen-
tixol preventing relapse in patients with schizophrenia appears to be similar to that 
of other ﬁrst and second generation antipsychotics. However, the low treatment costs 
for patients treated with ﬂupentixol might be explained by the small number of 
patients who were hospitalised (70 insured) and the larger share of patients treated 
with its depot formulation.
PMH45
COST-UTILITY OF AGOMELATINE, VENLAFAXINE AND PLACEBO IN 
THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN 
FINLAND—ECONOMIC MODELLING STUDY USING REPRESENTATIVE 
POPULATION DATA
Soini EJ, Hallinen TA
ESiOR Oy, Kuopio, Finland
OBJECTIVES: A cost-utility analysis of a new antidepressant agomelatine (Valdoxan) 
compared to generic venlafaxine and placebo in the treatment of MDD was performed 
from the Finnish societal perspective. METHODS: The analysis is based on a Markov 
state transition model with second-order Monte Carlo simulation and two year time-
frame. Conservatively, agomelatine and venlafaxine were assumed to be equally effec-
tive in the treatment of depressive symptoms, but to differ in costs, side effect proﬁles, 
clinically signiﬁcant sleep disorders during treatment, discontinuation rates and dis-
continuation symptoms based on agomelatine clinical trials. Finnish EQ-5D utilities, 
health care resource use, travelling and production losses (derived from the actual 
work rates of MDD patients using human capital approach) were estimated based on 
a Finnish study including 298 patients with MDD, adjusted for confounders (age, 
gender, marital status, income and education), and matched to model states and 
adverse events using two-stage multivariate models. The costs were presented in 2008 
value. Annual discounting rate considered was 3%. RESULTS: Compared to generic 
venlafaxine and placebo the treatment with agomelatine resulted in 0.012 and 0.066 
additional quality-adjusted life-years (QALY) gained, and in 356 and a126 additional 
treatment costs during the two year time-frame, respectively. The corresponding 
additional costs including production losses were 220 and a3255. Agomelatine was 
associated with an incremental treatment cost of a29,000/QALY gained compared to 
generic venlafaxine. When production losses were included, this ratio fell to a18,000/
QALY gained. According to cost-effectiveness acceptability frontier (excl. production 
losses), the probability of agomelatine’s cost-effectiveness was 57 and 90% with the 
willingness-to-pay levels of a30,000 and a50,000 per QALY gained, respectively. 
Agomelatine dominated placebo. One-way sensitivity analyses showed that the results 
were robust to key parameter changes. CONCLUSIONS: Agomelatine is a cost-
 effective treatment for MDD versus generic venlafaxine and dominant versus placebo 
based on the representative Finnish data.
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ESTIMATING THE COSTS OF PSYCHIATRIC HOSPITAL SERVICES IN 
NIGERIA; A CASE STUDY OF FEDERAL NEUROPSYCHIATRIC HOSPITAL 
ENUGU, SOUTH EAST NIGERIA
Ezenduka CC
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OBJECTIVES: Little or no information exist on the cost of mental health services in 
Africa, even though mental health disorders represent a major public health concern 
in the region, in terms of health and economic impact. The study estimated the total 
and average/unit costs of psychiatric hospital services (including inpatients and out-
patients services) to guide policy and psychiatric hospital management efﬁciency in 
Nigeria. METHODS: The study was exploratory and analytical, examining 2008 data. 
Using standardized costing methodology based on ingredient approach, top-down 
methodology was combined with step-down approach to allocate resources (overhead 
and indirect costs) to the ﬁnal cost centers. All costs associated with treatment of the 
psychiatric patients (including annualised costs of capital items) were measured on 
aggregate basis as well as on per capita basis. Costs were calculated from the perspec-
tive of the health care facility, and converted to US Dollars at the 2008 exchange rate. 
RESULTS: Personnel costs average over 75% in all departments. Unit cost of outpa-
tient visit is similar to the cost of inpatient day averaging $50, while cost per inpatient 
admission is about $3288. Cost of emergency consultation is about two times the cost 
of an outpatient visit or inpatient day. About 65 new outpatients could be treated 
for the cost of one inpatient admission. Levels of subsidization for inpatients are 
over 90% while ancillary services are not subsidized hence full cost recovery. Cost of 
drugs is about 4.4% of the total costs and each prescription averaged $7.48. 
CONCLUSIONS: The unit cost estimates fall within the European estimates for 
 psychiatric health services and WHO-CHOICE’s ‘high estimates’ for tertiary health 
facilities in SSA. Adequate research is needed to determine the cost of providing 
 psychiatric hospital services in Africa to inform effective policy and improved man-
agement efﬁciency for mental health services in the region.
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OBJECTIVES: Clinical efﬁcacy and symptom control are the primary basis for atypical 
antipsychotic (AAP) selection. Clinical effectiveness outcomes are less well studied as 
treatment considerations. Retrospective administrative-claims data analyses for patients 
with schizophrenia and bipolar disorder were completed to characterize the association 
between AP treatment and clinical and economic patient outcomes. METHODS: 
Patients with schizophrenia (n  2737) or bipolar disorder (n  9707) on AAP (aripip-
razole, olanzapine, risperidone, quetiapine or ziprasidone) treatment were identiﬁed in 
the 2004–2005 PharMetrics Patient-Centric Database. Patients with q12 months con-
tinuous enrollment before and after their earliest AAP claim were included in the analy-
ses and stratiﬁed by their most-recent AAP claim. Treatment cohorts were propensity 
score matched. Index treatment differences were characterized by multivariable regres-
sion models. Time to discontinuation (Cox proportional hazard regression), psychiatric 
admission probability (logistic regression) and expenditures (GLM) were evaluated. 
Post–index period costs were tallied. RESULTS: Schizophrenia patient cohorts 
were aripiprazole (n  367), olanzapine (n  755), risperidone (n  1004), quetiapine 
(n  404) and ziprasidone (n  207). Mean age range was 40–44 years. After propensity 
score matching, there were no signiﬁcant differences across cohorts in time to discon-
tinuation and psychiatric hospitalization probability. Total quetiapine expenditures 
were greater than ziprasidone ($16,417 vs. $12,547; p  0.0024). CONCLUSIONS: 
Limited statistical differences were observed in this population. Further research should 
be conducted to understand whether such differences occur in other large databases 
and their clinical and economic relevance for AAP patient populations.
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PAROXETINE AND LITHIUM IN ACUTE BIPOLAR DEPRESSION
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OBJECTIVES: To evaluate the cost-effectiveness of quetiapine extended release 
300 mg once daily (o.d.) in adult patients with acute bipolar depression compared 
with average standard adult doses of paroxetine 20 mg o.d. and lithium 1.2 g o.d. 
METHODS: A weekly cycle 7-state markov model was designed to evaluate the cost-
effectiveness of quetiapine extended release over a 3-year time horizon from the per-
spective of the UK National Health Service. Remission, treatment-emergent mania, 
discontinuations, signiﬁcant weight-gain (q7%) and extrapyramidal adverse event rate 
probabilities were used in the model. These, in the form of relative risks, were obtained 
from two separate indirect comparisons of quetiapine extended release versus parox-
etine and lithium with placebo as the common comparator. These comparisons were 
obtained from randomised blinded studies in the AstraZeneca trial registry for que-
tiapine in the treatment of acute bipolar depression. A systematic literature review was 
completed to identify suitable health state utility values. Costs included pharmacologi-
cal therapy and resource use associated with the treatment of mood events. Results 
were reported in cost (2009 values) per quality-adjusted life years (QALYs). A proba-
bilistic sensitivity analysis (PSA) was conducted to assess the robustness of the results. 
RESULTS: Quetiapine extended release was a cost-effective treatment option for 
adults with acute bipolar depression versus both paroxetine and lithium. The deter-
ministic incremental cost-effectiveness ratios were £1,541/QALY and £14,548/QALY, 
when quetiapine extended release was compared with paroxetine and lithium, respec-
tively. These results were supported in the probabilistic sensitivity analysis. Eighty-four 
percent and 92% of simulations found quetiapine extended release to be cost-effective 
at a threshold of £30,000/QALY versus paroxetine and lithium, respectively. 
 CONCLUSIONS: The results of this cost-utility analysis suggest that not only is 
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quetiapine extended release effective but that it is also a cost-effective alternative 
compared with paroxetine and lithium in the management of adult patients with acute 
bipolar depression.
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OBJECTIVES: To evaluate the cost-effectiveness of quetiapine extended release 
300 mg once daily (o.d.) in adult patients with acute bipolar depression compared 
with other atypical antipsychotics. METHODS: A systematic literature review was 
conducted to inform a mixed treatment comparison utilising a Markov Chain Monte 
Carlo simulation comprising of a random effects model to estimate the risk of remis-
sion, treatment-emergent mania, discontinuations, signiﬁcant weight-gain (q7%) and 
extrapyramidal adverse event. A weekly cycle 7-state markov model was designed to 
evaluate the cost-effectiveness of quetiapine extended release over a 3-year time 
horizon from the perspective of the UK National Health Service. A systematic litera-
ture review was completed to identify suitable health state utility values. Costs 
included pharmacological therapy and resource use associated with the treatment of 
mood events. Results were reported in cost (2009 values) per quality-adjusted life 
years (QALYs). A probabilistic sensitivity analysis (PSA) was conducted to assess the 
robustness of the results. RESULTS: The literature review only identiﬁed two other 
atypical antipsychotics with a sufﬁcient quality of data to be included in the analysis, 
olanzapine 10 mg and aripiprazole 15 mg (In the aripiprazole trials, aripiprazole did 
not reach signiﬁcance at 8-weeks versus placebo, the data was included for complete-
ness). Quetiapine extended release was a cost-effective (cost: £11,568; QALYs: 2.351) 
treatment option dominating both olanzapine (cost: £11,584; QALYs: 2.347) and 
aripiprazole (cost: £11,773; QALYs: 2.328). These results were supported in the 
probabilistic sensitivity analysis. CONCLUSIONS: The results of this cost-utility 
analysis suggest that not only is quetiapine extended release effective but that it is also 
a cost-effective alternative versus other atypical antipsychotics in the management of 
adult patients with acute bipolar depression.
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OBJECTIVES: To describe the concordance between remission according to clinical 
diagnostic orientation and remission obtained from the computerized databases of 
patients with major depression (MD) in a Spanish population. METHODS: Design: 
multicenter transversal. The assessed population was comprised by people over 17 
from reformed primary care facilities, who had a MD episode between January 2003 
and March 2007. A specialist in psychiatry assessed a random sample of patient his-
tories and determined whether a certain patient was in remission according to clinical 
criteria. Regarding the databases, patients were considered in remission when they did 
not need further prescriptions of AD for at least 6 months after completing treatment 
for a new episode. Validity indicators (sensitivity [S], speciﬁcity [Sp]) and clinical 
utility (positive and negative probability ratio [PPR] and [NPR]) were calculated. The 
concordance index was established using Cohen’s kappa coefﬁcient. Signiﬁcance level 
was p  0.05. RESULTS: 4,572 subjects were analyzed. 54.6% (CI of 95%: 53.2–
56.0%) were considered in remission. Patients in remission showed lower: age (52.6 
vs. 60.7), proportion of women (71.7% vs. 78.2%), general morbidity (6.2 vs. 7.7 
episodes/year), RUB/year (2.7 vs. 3.0), sick leave days (31.0 vs. 38.5) and treatment 
duration (146.6 vs. 307.7 days); p  0.01. 133 patient histories were reviewed. The 
kappa coefﬁcient was 82.8% (conﬁdence intervals [CI] were 95%: 73.1—92.6), PPR 
9.8% and NPR 0.1%. Allocation discrepancies between both criteria were found in 
11 patients. S was 92.5% (CI was 95%: 88.0–96.9%) and Sp was 90.6% (CI was 
95%: 85.6–95.6%), p  0.001. Reliability analysis: Cronbach’s alpha: 90.6% (CI was 
95%: 85.6–95.6%). CONCLUSIONS: Results show an acceptable level of concor-
dance between remission obtained from the computerized databases and clinical 
 criteria. The major discrepancies were found in diagnostic accuracy.
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TRENDS IN RATES OF PEDIATRIC BIPOLAR DISORDER-RELATED 
HOSPITALIZATIONS AND RELATED RESOURCE USE IN THE UNITED 
STATES
Jackel J1, Davis KL2, Candrilli SD2
1RTI Health Solutions, Waltham, MA, USA, 2RTI Health Solutions, Research Triangle Park, 
NC, USA
OBJECTIVES: Bipolar disorder is a serious mental illness characterized by cyclical 
periods of depression and euphoria. Few studies have evaluated the inpatient burden 
of bipolar disorder among pediatrics. This study explored rates of hospitalization, 
length of stay (LOS), and total charges (TC) associated with bipolar disorder in a 
pediatric population over a six-year period. METHODS: Data were taken from the 
2000–2005 Healthcare Cost and Utilization Project Nationwide Inpatient Samples, 
nationally representative databases of United States (US) hospital stays. Pediatric (a19 
years) patients with a primary diagnosis of bipolar disorder (ICD-9-CM codes 296.0 
and 296.5–296.9) were analyzed. Weighted, age-standardized hospitalization rates, 
patient demographics, and estimates of TC and LOS were assessed. RESULTS: 
Over the 6-year study period, 212,964 pediatric visits with a primary diagnosis of 
bipolar disorder were identiﬁed. Mean (oSD) age was 14.7 (o3.4) years and 48.7% 
were female. Most (47.8%) were routine admissions, and the majority was covered 
by private insurance (51.2%). The age-standardized rate of bipolar disorder-related 
hospitalizations (per 10,000 2008 US pediatric population) rose slightly from 2000 to 
2005, from 3.4/10,000 to 3.8/10,000, with a low of 2.8/10,000 in 2002 and a high 
of 4.2/10,000 in 2003. Early in the decade, the mean LOS rose (8.2 days in 2000 to 
9.6 in 2002), but then declined, to 7.8 days in 2005. Similarly, mean TC (2008 US$) 
for a bipolar disorder-related stay increased between 2000 and 2002 ($12,744 to 
$16,567, respectively), and then declined over the next 3 years, to $13,736 in 2005. 
CONCLUSIONS: We examined trends in rates of bipolar disorder-related hospitaliza-
tions and associated outcomes among pediatric patients. We observed fairly stable rates 
of hospitalizations over the 6-year study period. However, LOS and TC exhibited an 
initial rise and subsequent decline. Health care stakeholders should be cognizant of the 
effect that bipolar disorder may have on hospitalizations and related resource use.
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PATIENT-REPORTED OUTCOMES IN A VULNERABLE POPULATION: A 
PILOT STUDY CONDUCTED WITH A NOVEL PATIENT COMMUNITY
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OBJECTIVES: Previous studies have demonstrated the ability to collect patient-
reported outcomes from members of an on-line patient community with chronic condi-
tions. In this pilot study, we explore the feasibility of capturing health resource 
utilization data from a vulnerable population, schizophrenics. METHODS: To iden-
tify 50 subjects, we screened 369 iGuard.org members taking at least one anti- 
psychotic: aripiprazole, clozapine, haloperidol, olanzapine, paliperidone, quetiapine, 
risperdone, or ziprasidone. iGuard.org is a medication monitoring service that pro-
vides drug safety information to over 1.4 million US members. Subjects completed an 
on-line survey regarding health resource use in the past 6 months and 2 years, among 
other questions. RESULTS: A total of 45 of 50 respondents (90%) identiﬁed them-
selves as a patient; 10% were caregivers. Most respondents (80%) are managed by 
a psychiatrist and have experienced metabolic symptoms: 68% gained 11 pounds, 
14% gained 10 pounds or less, 38% were diagnosed with high cholesterol, and 10% 
developed diabetes. Only 16% have not experienced metabolic symptoms. With 
respect to resource utilization, 44% visited the ER, 24% were hospitalized, and 12% 
were arrested, jailed, or imprisoned in the past 6 months. Utilization within the last 
2 years was as follows: 68% visited the ER, 40% were hospitalized, and 12% were 
arrested. Responses were inconsistent for a total of 5 of 50 patients who indicated use 
within the past 6 months, but not within 2 years in at least one of the three resource 
categories. CONCLUSIONS: The results of this study suggest that although research-
ers should continue to examine patient reported data for inconsistencies, patient 
communities can be a time and cost-efﬁcient source of patient-reported outcomes data 
such as health resource utilization even for vulnerable populations.
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OBJECTIVES: To identify utilization patterns of health care resources for psychoso-
cial supports in Japanese psychiatric outpatients. METHODS: A one-day survey was 
conducted at 109 outpatient mental clinics from members of the Japanese Association 
of Neuro-Psychiatric Clinics during the period from December 10 to 16, 2008. All 
patients who visited the clinics on the day of survey were subjected to the study and 
medical staffs ﬁlled out questionnaires on patients’ socio-demographic and clinical 
status including information about resource utilization for psychosocial supports. 
RESULTS: Among total 4689 patients, 42.2% were male. The mean / SD age was 
47.1 o 17.2 years. More than two thirds of patients (37.9%) were diagnosed as mood 
disorders (ICD-10 F3), followed by neurotic disorders (F4: 27.7%), psychotic disor-
ders (F2: 20.0%), organic mental disorders (F0: 2.7%) and other diagnosis (8.8%). 
18.9% patients had been hospitalized at psychiatric institutions at least once. 9.8% 
consulted medical staffs such as psychologists and social workers, in addition to psy-
chiatrists. 4.2% of patients utilized day/nightcare programs covered by health insur-
ance. Utilization rate of community services including community workshops, support 
service for employment, local activity support center, rehabilitation service and other 
psychosocial resources were 2.0%, 1.3%, 0.9%, 0.2% and 1.1%, respectively. 
 DISCUSSION: In Japan, in most cases, consultations by medical staffs are not covered 
by health insurance but free of charge. Meanwhile, based on “the Services and Sup-
ports for Persons with Disabilities Act”, community services are provided at a cost of 
municipalities. Under such a circumstance, many of Japanese patients with mental 
disorders utilize psychosocial supports provided by local governments as well as those 
covered by health insurance. CONCLUSIONS: Costs for psychosocial supports borne 
by local governments is not included in health care cost. However, when conducting 
pharmacoeconomic analysis of psychotropics in Japan, it should be taken into 
account.
